We need to plan now. After developing a vaccine, the next challenge will involve its allocation. — Reuters
IN the race to develop a Covid-19 vaccine, a lot of attention has been paid to the types of vaccines being developed and their progress through the various stages of clinical trial. A lot less attention has been paid to what happens after a vaccine is approved by the regulators.
As recognised by a US scientific committee, governments need to start planning how they will distribute a vaccine efficiently and fairly, because, when a vaccine is approved, most countries won’t have enough doses to vaccinate everyone.
Already a subscriber? Log in
Save 30% OFF The Star Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
